MediciBioㅣ메디치바이오

MediciBio’s next-generation LNP platform leverages proprietary ionizable lipids to overcome the limitations of conventional LNP technologies, enabling local or systemic delivery with improved performance.

Systemic Delivery Technology

Systemic Delivery LNP is designed to overcome one of the key challenges of conventional systemic LNPs—immune activation and reduced efficacy upon repeated dosing. Following intravenous (IV) administration, this advanced LNP minimizes immunogenicity, enabling consistent performance across multiple doses.

With its repeat-dose profile, it is ideally suited for the development of mRNA and siRNA-based gene therapies, mRNA-encoded antibodies, and in vivo CAR therapies

Local Delivery Technology

Local Delivery LNP technology is engineered to remain at the injection site following intramuscular (IM) administration, minimizing systemic circulation. By limiting LNP distribution, this approach significantly reduces systemic inflammatory responses (reactogenicity) often associated with conventional mRNA vaccines.

This localized delivery advantage enables the development of safer and more targeted mRNA-based solutions — from infectious disease and cancer vaccines to therapeutics for localized conditions such as joint disorders

MediciBio's LNP platform enables targeted delivery to the spleen or lungs, expanding therapeutic options utilizing proprietary targeting lipids for organ-specific biodistribution. Spleen-targeted LNPs are ideal for cancer immunotherapy, autoimmune disease, and in vivo CAR-T generation. Lung-targeted LNPs support treatment of genetic lung diseases, respiratory infections, and lung cancer.
By optimizing tissue-specific delivery, we enhance efficacy and minimize off-target effects. This approach unlocks next-generation mRNA and gene therapies tailored to each organ.

MediciBio’s Active Targeting LNP technology utilizes a range of targeting ligands—such as aptamers and antibodies—without requiring chemical conjugation, enabling gene-loaded LNPs to selectively bind to target cells and enhance intracellular delivery. The platform supports precise targeting of both cancer cells and immune cells, including T cells, monocytes, macrophages, and NK cells. With its versatile and scalable targeting capability, it holds strong promise for advancing next-generation mRNA and siRNA-based cancer therapies, immunotherapies, and in vivo CAR therapies.

MediciBio’s next-generation LNP platform leverages proprietary ionizable lipids to overcome the limitations of conventional LNP technologies, enabling local or systemic delivery with improved performance.

Systemic Delivery Technology

Systemic Delivery LNP is designed to overcome one of the key challenges of conventional systemic LNPs—immune activation and reduced efficacy upon repeated dosing. Following intravenous (IV) administration, this advanced LNP minimizes immunogenicity, enabling consistent performance across multiple doses.

With its repeat-dose profile, it is ideally suited for the development of mRNA and siRNA-based gene therapies, mRNA-encoded antibodies, and in vivo CAR therapies.

Local Delivery Technology

Local Delivery LNP technology is engineered to remain at the injection site following intramuscular (IM) administration, minimizing systemic circulation. By limiting LNP distribution, this approach significantly reduces systemic inflammatory responses (reactogenicity) often associated with conventional mRNA vaccines.

This localized delivery advantage enables the development of safer and more targeted mRNA-based solutions — from infectious disease and cancer vaccines to therapeutics for localized conditions such as joint disorders.

MediciBio's LNP platform enables targeted delivery to the spleen or lungs, expanding therapeutic options utilizing proprietary targeting lipids for organ-specific biodistribution. Spleen-targeted LNPs are ideal for cancer immunotherapy, autoimmune disease, and in vivo CAR-T generation. Lung-targeted LNPs support treatment of genetic lung diseases, respiratory infections, and lung cancer.
By optimizing tissue-specific delivery, we enhance efficacy and minimize off-target effects. This approach unlocks next-generation mRNA and gene therapies tailored to each organ.

MediciBio’s Active Targeting LNP technology utilizes a range of targeting ligands—such as aptamers and antibodies—without requiring chemical conjugation, enabling gene-loaded LNPs to selectively bind to target cells and enhance intracellular delivery. The platform supports precise targeting of both cancer cells and immune cells, including T cells, monocytes, macrophages, and NK cells. With its versatile and scalable targeting capability, it holds strong promise for advancing next-generation mRNA and siRNA-based cancer therapies, immunotherapies, and in vivo CAR therapies.

PIPELINE

MDC-002

Medici Ionizable Lipids to overcome the limitations of conventional LNPs

MDC-004

Organ-targeted LNPs for the spleen and lung using proprietary passive targeting lipids

MDC-007

MDC-002 : Medici Ionizable Lipids to overcome the limitations of conventional LNPs

MDC-004 : Organ targeted LNP platforms utilizing proprietary targeting lipids

MDC-007 : Active targeting LNP platforms utilizing physical ligation of diverse antibodies or aptamers